Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 538

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 5
Chunk 538
---
 the United States, Europe, China and other major markets.
We believe that our globally-facing strategy of focusing on drug development for novel but relatively well-characterized targets and for validated targets, in combination with our development of multiple drug candidates concurrently and testing them for multiple indications and in combinations with other drugs, enhances the likelihood that our research and development efforts will yield successful drug candidates. Nonetheless, we cannot be certain if any of our drug candidates will receive new or additional regulatory approvals. Even if such approvals are granted, we will need to thereafter establish manufacturing supply and engage in extensive marketing prior to generating any revenue from such drugs. The effectiveness of our marketing will depend on the efforts of our dedicated oncology team in China and our collaboration partners in the rest of the world. The ultimate commercial success of our drugs will depend on their acceptance by patients, the medical community and third-party payors and their ability to compete effectively with other therapies on the market.
To date, surufatinib and savolitinib have been approved for sale in China and fruquintinib has been approved for sale in China, the U.S., E.U., Japan, Argentina, Switzerland, Canada, United Kingdom, Australia, Singapore, Israel, South Korea and the United Arab Emirates.
Our manufacturing site in Suzhou produces both clinical and commercial supplies of fruquintinib and surufatinib. With the establishment of our new manufacturing site in Pudong, Shanghai, which is expected to increase our manufacturing capacity by over five times, all our clinical supplies have completed technical transfer and are now coming from our Shanghai factory. Our commercial supplies have gradually migrated to this Shanghai factory. In the end of 2024, our first commercial batch of savolitinib, which previously relied on third-party manufacturer, was produced in our Shanghai factory and supplied to our partner. Beginning in October 2020, we assumed responsibility for the development and execution of all on-the-ground medical detailing, promotion and local and regional marketing activities in China for Elunate. Sulanda is marketed by us in China without the support of a collaboration partner. However, we have a limited history of commercializing our internally developed drug candidates, which makes it difficult to evaluate our future prospects.
​

The competitive environment is also an important factor with the commercial success of our potential global first-in-class products, such as sovleplenib, depending on whether we are able to gain regulatory approvals and quickly bring such products to market ahead of competing drug candidates being developed by other companies.
For